Study Addresses HIV-Infected Prostate Cancer Patients’ Treatment Disparities

Study Addresses HIV-Infected Prostate Cancer Patients’ Treatment Disparities
shutterstock_204149257There has been an unresolved medical question regarding prostate cancer treatment in HIV-infected (HIV+) men. Even though it is known these men face cancer treatment disparities that impact outcome, the appropriate medical care in these patients remains unknown. To address these topics, a team of researchers from the Northwestern University Feinberg School of Medicine, Chicago, IL, lead by Dr. Adam B. Murphy, recently published their results titled “Are HIV-Infected Men Vulnerable to Prostate Cancer Treatment Disparities?” in the Cancer Epidemiology, Biomarkers & Prevention journal. Researchers used an electronic chart review to design a retrospective cohort study. From 2001 to 2012, the team analyzed a total of 43 HIV+ patients with prostate cancer, along with 86 age- and race-matched HIV-uninfected (HIV) controls with prostate cancer (with ages ranging from 40 to 79 years). Using the National Comprehensive Cancer Network guidelines the appropriate treatment was defined. Furthermore, the Charlson comorbidity index (CCI) was the reference used to estimate life expectancy. The results demonstrated that men were diagnosed with prostate cancer at a median age of 59.5 years and the median
Subscribe or to access all post and page content.